{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"71"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"Progression was defined as any one or more of the following:\n\n* Serum M protein increase ≥ 25% from baseline (or an increase of ≥ 1 g/dL if serum M protein was ≥ 5 g/dL at baseline), with an absolute increase of ≥ 0.5 g/dL; or\n* Urine M protein increase ≥ 25% from baseline, with an absolute increase of ≥ 200 mg/24 hrs; or\n* If patient had serum M protein \\< 1 g/dL, urine M protein \\< 200 mg/24 hrs, and an involved serum free light chain level ≥ 10 mg/dL at baseline: ≥ 25% increase in the difference between involved and uninvolved serum free light chain level, with an absolute increase of ≥ 10 mg/dL; or\n* Bone marrow plasma cell percentage increase ≥ 25% from baseline, with the absolute plasma cell % ≥ 10%; or\n* New bone lesions or soft tissue plasmacytomas, or definite increase in size of existing bone lesions or soft tissue plasmacytomas; or\n* Development of hypercalcemia (corrected serum calcium \\> 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to multiple myeloma.","groups":[{"description":"Revlimid: 10 mg/day in the morning same time each day","id":"OG000","title":"Revlimid"},{"description":"No treatment","id":"OG001","title":"Observation"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}